Quick summary

Terminalia chebula, commonly known as Haritaki, is a medicinal plant widely studied for its traditional use and diverse pharmacological properties. It contains numerous bioactive compounds including tannins, phenolic acids, flavonoids, and triterpenes. Preclinical and some clinical evidence suggest potential antioxidant, anti-inflammatory, antimicrobial, hepatoprotective, neuroprotective, and antidiabetic effects. The herb is a key component of formulations like Triphala and is examined for various health applications including oral health, metabolic syndrome, and post-COVID-19 condition. While traditional use and preclinical data are substantial, high-quality clinical studies remain limited, and safety data are not comprehensive.

What is it

Haritaki (Terminalia chebula) is a medicinal plant traditionally used in Ayurvedic medicine. Its fruits are rich in various bioactive compounds such as tannins, phenolic acids, flavonoids, and triterpenes that contribute to its pharmacological profile. It is often used both as a single herb and as part of herbal formulations like Triphala.

Traditional uses

Haritaki has been traditionally used for a range of purposes including digestive health support, detoxification, oral hygiene, and to promote general wellness. It is a key ingredient in Triphala, a classical Ayurvedic formulation employed for digestive, detoxifying, and anti-inflammatory effects.

Active compounds

  • Tannins
  • Phenolic acids
  • Flavonoids
  • Triterpenes

Potential benefits with evidence levels

  • Antimicrobial effects in oral health (Moderate evidence):
    Systematic reviews and meta-analyses suggest that herbal oral care products containing Terminalia chebula can reduce dental plaque, gingival inflammation, and cariogenic bacteria such as Streptococcus mutans. Triphala, including Terminalia chebula, has shown antimicrobial activity comparable to chlorhexidine as a root canal irrigant, with a favorable safety profile.
  • Antioxidant and anti-inflammatory effects (Preclinical and preliminary clinical evidence):
    Extracts demonstrate antioxidant and anti-inflammatory properties possibly beneficial for gastrointestinal disorders, metabolic syndrome, and reducing oxidative stress and inflammation after COVID-19. However, human data remain preliminary and require further clinical trials.
  • Hepatoprotective effects (Preclinical evidence):
    Tannin-rich fractions including Terminalia chebula have shown hepatoprotective activity in animal studies by lowering liver enzyme markers and aiding hepatic function recovery. Human clinical validation is still needed.
  • Metabolic syndrome and lipid profile improvement (Preclinical and limited clinical evidence):
    The herb may improve lipid profiles and metabolic parameters in populations at risk for metabolic syndrome and type 2 diabetes, although controlled human studies are scarce.
  • Potential immunomodulatory effects (Limited preclinical and emerging clinical evidence):
    Some studies indicate immunomodulatory properties that might contribute to benefits in chronic diseases, but robust clinical data are lacking.

Side effects

No significant or severe adverse effects explicitly linked to Terminalia chebula have been reported in clinical trials analyzed. Some users of herbal mouthwashes containing the herb reported acceptable taste and satisfaction without major side effects. However, underreporting or limited rigorous adverse event monitoring in studies means rare or long-term effects cannot be excluded.

Drug interactions

There is no conclusive clinical evidence regarding drug interactions involving Terminalia chebula. Given general challenges with herbal products, potential interactions cannot be ruled out, and caution along with medical supervision is advised when used with other medications.

Who should avoid it

Specific contraindications have not been established based on current evidence. Clinical prudence is recommended for people with comorbidities, those taking concomitant medications, and during pregnancy or breastfeeding due to insufficient safety data. Use in these populations should be approached cautiously and under medical supervision.

Evidence limitations

  • Most evidence derives from preclinical and in vitro studies, limiting direct applicability to humans.
  • Available clinical trials have small sample sizes, short durations, and use heterogeneous formulations.
  • Safety monitoring and adverse effect reporting have been incomplete in many studies.
  • Lack of high-quality, large-scale randomized controlled trials specifically on Terminalia chebula alone.
  • Some clinical evidence is indirect, coming from formulations containing multiple herbs including Terminalia chebula.
  • Variations in dosing, extraction methods, and product standardization hamper reproducibility and interpretation.

References

Last reviewed

June 2024

Informational disclaimer

This page is for informational purposes only and does not constitute medical advice. The effects of herbal products can vary between individuals, and their use should be approached cautiously. Always consult a qualified healthcare provider before starting any new supplement, especially if you are pregnant, breastfeeding, have underlying health conditions, or are taking other medications.